[ad_1]
German pharmaceutical company CureVac reveals amazing results in its mRNA tests Covid-19 vaccine, the slowdown is expected to help meet the global need for effective inoculation.
CureVac said on Wednesday that its blow was 47 percent effective in the provisional analysis of late-stage tests to protect against coronavirus, making it the most effective of the coronavirus vaccines tested to date.
Earlier this week, U.S. drug pharmacist Novavax said it was a protein-based shooting 90 percent effective Modern and BioNTech / Pfizer owners are 95 percent resistant to the original strain of the virus when it comes to fighting coronavirus.
Shares of CureVac’s Nasdaq were down 50 percent after the New York market.
The company attributed the deplorable results to the new strains of the virus that were circulating in 10 countries in Latin America and across Europe, as tests were carried out.
In a study of 40,000 people, CureVac said 13 variants were found in volunteers, more than half of all cases of coronavirus caused by the variant of concern.
However, UK data this week showed two doses of BioNTech / Pfizer messenger mRNA or ribonucleic acid, 96 percent of the vaccine was effective in preventing the hospitalization of those infected with the Delta variant that was first detected in India.
This week the U.S. Centers for Disease Control and Prevention added Delta strain to the list of variants of concern.
CureVac has partnered with German manufacturing conglomerate Bayer to produce the coronavirus vaccine and has an agreement with British pharmaceutical company GlaxoSmithKline to create the next generation of owners.
The poor results of the trials call into question the viability of these projects. CureVac aims to produce 300m doses of its vaccine this year and 20 billion in 2022.
“While we hoped to achieve a stronger interim result, we recognize that it is a challenge to show great effectiveness in this vast diversity of unprecedented variants,” said Franz-Werner Haas, CEO of CureVac. He added that many of the variants “emphasize the importance of developing next-generation vaccines.”
The vaccine is also being studied in the UK as part of a booster trial that involves giving different shots to people who have already received two doses of Oxford / AstraZeneca or BioNTech / Pfizer vaccines.
Like modern and BioNTech / Pfizer vaccines, the owner of CureVac uses mRNA but its mRNA is natural and unchanged. His shot uses a lower dose, 12 micrograms, compared to Modern’s 100 mg and BioNTech / Pfizer’s 30 mg. This has a lower production cost and is stable at normal refrigerator temperatures.
CureVac said it will continue with two-dose mRNA vaccine trials and decide on the most appropriate regulatory route after evaluating the final trial data.
Coronavirus business update
How is the coronavirus taking over in markets, businesses, and in our daily lives and workplaces? Keep up to date with our coronavirus newsletter. Register here
[ad_2]
Source link
